Report Processing. Please wait...

Report Results - Tabulated Chart Abstraction Data

Review the tabulated results from the first data abstraction. After reviewing the chart data below, select the quality measure(s) you would like to focus on during the improvement phase by checking the box to the left of each quality measure. You must select at least one quality measure and approve the report by clicking the submit button at the bottom of the page.

After analyzing the report data, select quality measure(s) for the improvement phase that you performed less than expected on or that will have a meaningful impact on your practice.

	Examine Systems: Practice Characteristics
	Type of practice: Single specialty group, > 10 physicians
	You provide mainly: Consultative Care
	Patient Chart Format: Electronic Medical Records (EMR)

Select	Demographics	n	%	avg
	Male	18	72
	Female	7	28
	Age Distribution
	under 30	3	12
	30 - 44	3	12
	45 - 59	1	4
	60 and over	18	72
	Race
	African American/Black	3	12
	American Indian/Alaskan Native	0	0
	Native Hawaiian/Pacific Islander	1	4
	Asian	1	4
	Caucasian/White	8	32
	Other Race	0	0
	No Race Specified	1	4
	Ethnicity
	Hispanic/Latino	4	16
	Not Hispanic/Latino	16	64
	Patient Care
	Sole usual source of care for patient's gout	17	68
	Tabulated Chart Abstraction Data
	Confirmed diagnosis of gout	25	100
	Allopurinol adjustment for renal function ^QI
	Patients receiving an initial prescription for allopurinol	15	60
	INITIALLY PRESCRIBED BY YOU:
	Patients receiving an initial prescription for allopurinol	13	52
	Patients receiving an initial prescription for allopurinol having significant renal impairment	3	23
	Patients receiving an initial prescription for allopurinol having significant renal impairment and initial daily allopurinol dose less than 300 mg/day	2	67
	INITIALLY PRESCRIBED BY OTHER PHYSICIAN:
	Patients receiving an initial prescription for allopurinol	2	8
	Patients receiving an initial prescription for allopurinol having significant renal impairment	1	50
	Patients receiving an initial prescription for allopurinol having significant renal impairment and initial daily allopurinol dose less than 300 mg/day	0	0
	Anti-inflammatory agents with initiation of urate-lowering agents ^QI
	Patients with tophaceous gout	13	52
	Patients with tophaceous gout given an initial prescription for a urate-lowering medication	7	54
	INITIALLY PRESCRIBED BY YOU:
	Patients with tophaceous gout given an initial prescription for a urate-lowering medication	6	46
	Patients with tophaceous gout given an initial prescription for a urate-lowering medication lacking both significant renal impairment and peptic ulcer disease	2	33
	Patients with tophaceous gout given an initial prescription for a urate-lowering medication lacking both significant renal impairment and peptic ulcer disease given a prophylactic agent concomitantly	1	50
	INITIALLY PRESCRIBED BY OTHER PHYSICIAN:
	Patients with tophaceous gout given an initial prescription for a urate-lowering medication	1	8
	Patients with tophaceous gout given an initial prescription for a urate-lowering medication lacking both significant renal impairment and peptic ulcer disease	1	100
	Patients with tophaceous gout given an initial prescription for a urate-lowering medication lacking both significant renal impairment and peptic ulcer disease given a prophylactic agent concomitantly	1	100
	Apropriate urate-lowering agent ^QI
	Patients with a history of nephrolithiasis OR significant renal insufficiency	19	76
	Patients with a history of nephrolithiasis OR significant renal insufficiency with a xanthine oxidase inhibitor started as the initial urate-lowering medication rather than a uricosuric agent	13	68
	Patients with a history of nephrolithiasis OR significant renal insufficiency with a uricosuric agent started	4	21
	Initiation of urate-lowering therapy ^QI
	Patients with hyperuricemia and gouty arthritis	22	88
	Patients with hyperuricemia and gouty arthritis where a urate-lowering drug is NOT prescribed due to:
	Not Indicated	1	5
	Contraindicated	2	9
	Patient refused	1	5
	Other reason	0	0
	Patients with hyperuricemia and gouty arthritis offered therapy with a urate-lowering drug	18	82
	Drug Safety
	Informing patients about risks^QI
	INITIALLY PRESCRIBED BY YOU:
	Number of patients newly prescribed allopurinol	4	16
	For patients newly prescribed allopurinol, a documented discussion was held with the patient about the risks of the chosen therapy	4	100
	Number of patients newly prescribed probenicid	6	24
	For patients newly prescribed probenicid, a documented discussion was held with the patient about the risks of the chosen therapy	5	83
	Number of patients newly prescribed colchicine	5	20
	For patients newly prescribed colchicine, a documented discussion was held with the patient about the risks of the chosen therapy	3	60
	Number of patients newly prescribed NSAIDs	6	24
	For patients newly prescribed NSAIDs, a documented discussion was held with the patient about the risks of the chosen therapy	2	33
	Number of patients newly prescribed glucocorticoids	3	12
	For patients newly prescribed glucocorticoids, a documented discussion was held with the patient about the risks of the chosen therapy	0	0
	Number of patients newly prescribed narcotics	0	0
	INITIALLY PRESCRIBED BY OTHER PHYSICIAN:
	Number of patients newly prescribed allopurinol	0	0
	Number of patients newly prescribed probenicid	0	0
	Number of patients newly prescribed colchicine	0	0
	Number of patients newly prescribed NSAIDs	1	4
	For patients newly prescribed NSAIDs, a documented discussion was held with the patient about the risks of the chosen therapy	0	0
	Number of patients newly prescribed glucocorticoids	2	8
	For patients newly prescribed glucocorticoids, a documented discussion was held with the patient about the risks of the chosen therapy	1	50
	Number of patients newly prescribed narcotics	0	0

	Prophylaxis for patients at risk for gastrointestinal bleeding^QI
	Number of patients treated with 1) a non-selective NSAID or 2) a COX-2 selective NSAID plus aspirin	0	0

	Lab monitoring - gastrointestinal bleeding ^QI
	Number of patients treated with a daily NSAID (selective or non-selective)	0	0

	Lab monitoring - renal insufficiency ^QI
	Number of patients treated with daily NSAIDs (selective or non-selective)	0	0

Laboratory monitoring for newly prescribed Drugs ^QI
Number of patients treated with Oral Glucocorticoids		4	16
DIAGNOSED BY YOU:		4
	with DEXA scan	4	100	1
	with Blood Pressure Check	4	100	1
	with Chemistry Panel	4	100	1
DIAGNOSED BY OTHER PHYSICIAN:		0
Laboratory monitoring for established Drugs ^QI
Number of patients treated with Oral Glucocorticoids		4	16
	with Urinalysis or Blood Glucose	3	75	1

	Examine Systems – Improvement Process Summary Below is a summary of what you reported in the Examine Systems – Improvement Process.
	Working well in the practice:

	The practice system for scheduling appointments tracks patients who cannot be accommodated within their desired timeframe and calls them back with openings.

	Could use improvement:
	The practice reduces the risk of delay in receiving care by performing triage of new patients requesting an appointment.
	The practice reduces the risk of delay in receiving care by instructing patients on when to call 911 or go to an emergency room rather than contact the practice.

	Not available or operational in the practice: